Target intelligence / Profile preview

Resistin-like molecule beta (RELM-β)

Target: RELM-β
Molecular classification: Cysteine-rich secreted cytokine, Peptide hormone, Member of the resistin-like molecule (RELM) family, Other (family of tissue-specific signaling molecules)

Overview

Resistin-like molecule beta (RELM-β) is a small, cysteine-rich secreted cytokine predominantly expressed by goblet cells and epithelial cells in the colon. It is a member of the resistin-like molecule family, sharing sequence structure with resistin and other RELMs. Functionally, RELM-β is implicated in maintenance of colonic barrier function, modulation of innate immunity, and regulation of susceptibility to colonic inflammation. It displays host-protective roles against intestinal nematode infections and affects the expression of immune regulatory genes, such as members of the REG3 family. Human and rodent RELM-β are selectively expressed in the gastrointestinal tract, especially the colon, and upregulated in inflammatory conditions and some cancers. While its receptors are not fully characterized, RELM-β is recognized as a relevant immunoregulatory molecule and a potential research target for gut-related inflammatory diseases.

Other names: RELM-βRELM-betaFIZZ2 (Found in Inflammatory Zone 2)HIMF-β (Hypoxia-Induced Mitogenic Factor beta)

Mechanism of action

Not applicable (no currently approved drugs directly targeting RELM-β)

Biological functions

Maintenance of colonic epithelial barrier functionRegulation of innate immunity, especially in the gastrointestinal tractModulation of susceptibility to colonic inflammationAntiparasitic activity (nematode immunity)Modulation of intestinal homeostasisPossible inhibition of adipocyte differentiationModulates expression of innate immunity mediators (e.g., REG3β, REG3γ)

Disease associations

Inflammatory bowel disease (colonic inflammation)Allergic gastroenteropathyGastrointestinal nematode infection/immunityPotentially cancer (expression increased in colon tumors)Possibly involved in asthma and TH2 lung disease models

Safety considerations

No direct human therapeutics target RELM-β, so drug-specific safety profiles are not establishedAltered RELM-β activity is associated with differential susceptibility to colitis and may be involved in processes such as epithelial barrier integrity and control of harmful inflammation, suggesting that manipulation could have risks related to gut immunity and inflammationManipulating its activity in disease may increase risk of either immunosuppression or excessive inflammation

Biomarkers

RELM-β levels in human plasma and colonic tissue have been studied as biomarkers for colonic inflammation and intestinal barrier integrity in research settingsNot an established clinical biomarker

Beyond the preview

Go deeper on Resistin-like molecule beta (RELM-β).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resistin-like molecule beta (RELM-β).

Explore the full profile